Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Enterprise value

Enterprise value at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$12.92B+175%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.83B-51.1%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$1.72B+5.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.35B+176%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%
PVL
Palvella TherapeuticsPVLA
$1.58B—

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

$2.4Bmarket cap+$411.8Mtotal debt−$173.4Mcash and equivalents=$2.63B

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's enterprise value?
BioCryst Pharmaceuticals (BCRX) reported enterprise value of $2.63B in Q1 2026.
How has BioCryst Pharmaceuticals's enterprise value changed year-over-year?
BioCryst Pharmaceuticals's enterprise value increased by 46.7% year-over-year, from $1.79B to $2.63B.
What is the long-term trend for BioCryst Pharmaceuticals's enterprise value?
Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's enterprise value has grown at a 5.5% compound annual growth rate (CAGR), from $1.2B to $1.57B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.